Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Jefferies Upgrades Harmony Biosciences to Buy, Raises Price Target to $61

Jefferies analyst Chris Howerton upgrades Harmony Biosciences (NASDAQ:HRMY) from Hold to Buy and raises the price target from $57 to $61.
byBenzinga Newsdesk
October 14, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Jefferies analyst Chris Howerton upgrades Harmony Biosciences (NASDAQ:HRMY) from Hold to Buy and raises the price target from $57 to $61.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0